首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1033篇
  免费   84篇
  国内免费   18篇
耳鼻咽喉   3篇
儿科学   81篇
妇产科学   8篇
基础医学   85篇
口腔科学   26篇
临床医学   95篇
内科学   179篇
皮肤病学   27篇
神经病学   20篇
特种医学   132篇
外科学   112篇
综合类   135篇
预防医学   68篇
眼科学   4篇
药学   58篇
中国医学   39篇
肿瘤学   63篇
  2023年   8篇
  2022年   15篇
  2021年   23篇
  2020年   20篇
  2019年   15篇
  2018年   19篇
  2017年   14篇
  2016年   20篇
  2015年   27篇
  2014年   42篇
  2013年   37篇
  2012年   46篇
  2011年   50篇
  2010年   71篇
  2009年   60篇
  2008年   26篇
  2007年   28篇
  2006年   39篇
  2005年   31篇
  2004年   17篇
  2003年   25篇
  2002年   15篇
  2001年   13篇
  2000年   10篇
  1999年   19篇
  1998年   46篇
  1997年   63篇
  1996年   51篇
  1995年   38篇
  1994年   32篇
  1993年   33篇
  1992年   9篇
  1991年   6篇
  1990年   10篇
  1989年   23篇
  1988年   19篇
  1987年   17篇
  1986年   16篇
  1985年   10篇
  1984年   10篇
  1983年   2篇
  1982年   9篇
  1981年   8篇
  1980年   11篇
  1979年   3篇
  1977年   6篇
  1976年   6篇
  1975年   2篇
  1958年   4篇
  1957年   2篇
排序方式: 共有1135条查询结果,搜索用时 15 毫秒
51.
癌性疼痛是肿瘤最为常见的临床症状之一,如何有效地控制癌性疼痛,改善癌症病人的生活质量,延长生存期已成为全球关注的焦点。WHO调查认为:进展期癌症和终末期癌症病人约75%~90%以疼痛为主要临床症状,经过治疗90%的癌性疼痛可缓解。单纯运用西医的三阶梯镇痛疗法会导致病人药物成瘾性及较大的毒副作用;而单纯运用中医药疗法止痛效果不甚显著。因此,将中西医疗法结合运用到治疗癌性疼痛上,将成为今后癌症病人综合治疗的重要环节,尤其近年来中医学以其独特的理论体系,辨病辨证相结合,采用中药内服、外用、针灸等方法,对癌性疼痛的治疗研究取得了满意的进展。  相似文献   
52.
丁香水溶性化学成分的研究   总被引:2,自引:0,他引:2  
目的:研究丁香水溶性化学成分。方法:利用HP-20大孔吸附树脂、反相硅胶柱色谱、反相制备薄层色谱、制备型反相高效液相色谱进行分离,NMR和MS等方法进行结构鉴定。结果:从丁香干燥花蕾的水提物中分离鉴定了5个化合物,分别为槲皮素-3-O-葡萄糖醛酸苷(1),槲皮素-3-O-葡萄糖醛酸苷6″-甲酯(2),槲皮素-3-O-葡萄糖苷(3),丁香酚-β-芸香糖苷(4),杨梅酮(5)。结论:化合物1~4为首次从丁香属植物中分离得到。  相似文献   
53.
Aim: To describe cardiorespiratory fitness and body mass index (BMI) values in a representative population of 9-year-old Norwegian children in two rural communities and compare present values with previous findings.
Methods: Two hundred and fifty-nine 9-year-old children were invited, and 256 participated in this study. Maximal oxygen uptake was directly measured during a continuous progressive treadmill protocol. Body mass and height were also measured.
Results: The mean ± SD relative maximal oxygen uptake was 52.8 ± 6.5 for boys and 46.9 ± 7.2 mL/kg/min for girls. Eight percent of the boys and 16.8% of the girls were classified as overweight, and 1.6% of the boys and 6.9% of the girls as obese. Mean age, body mass, height and Ponderal index were not significantly different between sexes. Girls had a higher BMI than boys (p = 0.05).
Conclusion: Compared to earlier Norwegian studies, children's BMI values seem to have increased substantially. This increase is most pronounced in girls. When assessing these differences using the PI, this increase is less marked. Comparing maximal oxygen uptake data with that in earlier Nordic studies, there is no evidence that fitness has declined among 9-year olds. However, the limitations of the few earlier studies make reliable comparisons difficult.  相似文献   
54.
Peripheral nerve disorders may be classified into compressive or entrapment neuropathies and non‐compressive neuropathies. Muscle denervation recognized on MRI may be a useful sign in the diagnosis of peripheral nerve disorders. Acute or subacute denervation results in prolonged T2 relaxation time, producing increased signal in skeletal muscle on short tau inversion‐recovery and fat‐suppressed T2‐weighted images. Chronic denervation produces fatty atrophy of skeletal muscles, resulting in increased muscle signal on T1‐weighted images. This review will outline and illustrate the various ways that muscle denervation as seen on MRI may assist in the diagnosis and localization of peripheral nerve disorders.  相似文献   
55.
56.
BACKGROUND: Tumour necrosis factor-alpha (TNF-alpha) is an important regulator of the chronic inflammation contributing to tumour progression. Infliximab, an anti-TNF-alpha monoclonal antibody was investigated in this trial of patients with advanced cancer. The primary objectives were to determine the safety profile and biological response of infliximab in a cancer population. Clinical response was a secondary objective. PATIENTS AND METHODS: Forty-one patients received infliximab at 5 mg/kg (n = 21) or 10 mg/kg (n = 20) i.v. at 0 and 2 weeks and then every 4 weeks. Post-treatment samples were measured for changes in plasma and serum TNF-alpha, CCL2, IL-6 and C-reactive protein (CRP). RESULTS: Infliximab was well tolerated with no dose-limiting toxic effects. At both doses of infliximab, neutralisation of serum TNF-alpha was observed after 1 h while plasma CCL2, IL-6 and serum CRP were decreased 24 and 48 h following infliximab administration. Seven patients experienced disease stablisation (range 10-50+ weeks). There was no evidence of disease acceleration in any patient. CONCLUSIONS: Infliximab treatment was safe and well tolerated in patients with advanced cancer. There was evidence of biological activity with baseline TNF-alpha and CCL2 being correlated with infliximab response.  相似文献   
57.
This randomized controlled trial was designed to answer the question: does administration of dexamethasone to neonates with bronchopulmonary dysplasia decrease the need for assisted ventilation? Twenty-five infants with a birth weight < 1501 g, requiring mechanical ventilation and FiO2 of ± 0.30 at 21-35 days of age, were randomized to treatment with iv dexamethasone or to sham injections for 12 days. The primary outcome criterion was extubation within seven days after study entry. Treatment (n= 12) and control (n= 13) groups were well matched at entry. Dexamethasone facilitated weaning from assisted ventilation (p= 0.0154). There was no increased incidence of infection. Dexamethasone treatment resulted in a significant increase in glucosuria (p= 0.0002) and in systolic blood pressure (p= 0.0034). There was a significant decrease in heart rate (p= 0.0001) and a significant weight loss (p= 0.0002) following dexamethasone treatment. Dexamethasone treatment facilitated weaning from assisted ventilation but several systemic effects were noted that deserve further evaluation before dexamethasone becomes routine treatment.  相似文献   
58.
The effects of intermittent positive airway and continuous negative extrathoracic pressure ventilation on cerebral blood volume in preterm infants were studied using near infrared spectroscopy. In 12 infants continuous negative extrathoracic pressure caused a median decrease in cerebral blood volume of 0.14ml/100ml brain (95% confidence intervals (CI) 0.035–0.280) compared with no respiratory support. Oxygenated and deoxygenated haemoglobin also decreased, implying increased venous drainage as the main effect. In 17 infants intermittent positive pressure ventilation also caused a median reduction in cerebral blood volume of 0.06 ml/100 ml brain (95% CI 0.010–0.115) compared with endotracheal positive airway pressure. Deoxygenated haemoglobin increased by 0.07 ml/100 ml brain (95% CI 0.010–0.100) while oxygenated haemoglobin decreased by O.lOml/lOOml brain (95% CI 0.005–0.175). The increase in deoxygenated haemoglobin implies decreased venous drainage and the decrease in oxygenated haemoglobin implies that other factors may also be significant. Heart rate, blood pressure and oxygen saturation were monitored continuously and remained stable.  相似文献   
59.
目的:通过对突发性聋病人血中一氧化氮(NO)、丙二醛(MDA)、超氧化物歧化酶(SOD)含量的检洲,探讨突聋与血氧自由基和自由基的清除剂SOD之间的关系。方法:采用硝酸还原酶法测定了30例突聋病人血中NO含量,并以25例同期体检正常的健康人为对照组;同时还用硫代巴比妥酸比色法测定MDA含量,用黄嘌呤氧化酶法测定SOD含量。砖呆;应用金纳多、能量合剂、克林臭(即马来酸桂哌齐特,钙通道阻滞药)联合静脉输入,突聋各组的听力均有不同程度提高,有效率在78.57%以上。治疗后同对照组相比,血清NO、MDA水平明显低于患病之初,而SOD活性明显高于治疗之前,P〈0.01。结论;检测突聋病人血中N0、MDA、SOD的含量,能帮助我们探讨突聋的发病机理,估计预后。血氧自由基的升高可能是突聋发病因素之一,而SOD的含量可以帮助我们估计预后。  相似文献   
60.
Primary osteogenic sarcoma of the skull is an exceedingly rare condition. An adult male patient is described, who had a painless swelling in the right forehead that had rapidly enlarged in the previous 6 months. Radiological investigations showed a large destructive mass lesion involving the right side of the frontal bone with extension into the frontal sinus, causing marked extradural compression of brain parenchyma. Histopathological examination confirmed the lesion to be primary osteogenic sarcoma.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号